Skip to main content
main-content
Erschienen in: Breast Cancer Research and Treatment 2/2019

20.10.2018 | Clinical trial

Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study

verfasst von: Jean-Marc Classe, Cecile Loaec, P. Gimbergues, S. Alran, C. Tunon de Lara, P. F. Dupre, Roman Rouzier, C. Faure, N. Paillocher, M. P. Chauvet, G. Houvenaeghel, M. Gutowski, P. De Blay, J. L. Verhaeghe, E. Barranger, C. Lefebvre, C. Ngo, G. Ferron, C. Palpacuer, L. Campion

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

GANEA2 study was designed to assess accuracy and safety of sentinel lymph node (SLN) after neo-adjuvant chemotherapy (NAC) in breast cancer patients.

Methods

Early breast cancer patients treated with NAC were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent SLN and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement. The main endpoint was SLN false negative rate (FNR). Secondary endpoints were predictive factors for remaining positive ALND and survival of patients treated with SLN alone.

Results

From 2010 to 2014, 957 patients were included. Among the 419 patients from the cN0 group treated with SLN alone, one axillary relapse occurred during the follow-up. Among pN1 group patients, with successful mapping, 103 had a negative SLN. The FNR was 11.9% (95% CI 7.3–17.9%). Multivariate analysis showed that residual breast tumor size after NAC ≥ 5 mm and lympho-vascular invasion remained independent predictors for involved ALND. For patients with initially involved node, with negative SLN after NAC, no lympho-vascular invasion and a remaining breast tumor size 5 mm, the risk of a positive ALND is 3.7% regardless the number of SLN removed.

Conclusion

In patients with no initial node involvement, negative SLN after NAC allows to safely avoid an ALND. Residual breast tumor and lympho-vascular invasion after NAC allow identifying patients with initially involved node with a low risk of ALND involvement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
11.
Zurück zum Zitat El Hage Chehade H, Headon H, Kasem A, Mokbel K (2016) Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer: an update for clinical practice. Anticancer Res 36:1461–1471 PubMed El Hage Chehade H, Headon H, Kasem A, Mokbel K (2016) Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer: an update for clinical practice. Anticancer Res 36:1461–1471 PubMed
12.
Zurück zum Zitat Valachis A, Mamounas EP, Mittendorf EA et al (2018) Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis: recurrence after neoadjuvant chemotherapy. Cancer. https://​doi.​org/​10.​1002/​cncr.​31518 PubMedCrossRef Valachis A, Mamounas EP, Mittendorf EA et al (2018) Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: an international collaboration and individual patient meta-analysis: recurrence after neoadjuvant chemotherapy. Cancer. https://​doi.​org/​10.​1002/​cncr.​31518 PubMedCrossRef
17.
Zurück zum Zitat McCready DR, Yong WS, Ng AKT et al (2004) Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst 96:873–875 CrossRefPubMed McCready DR, Yong WS, Ng AKT et al (2004) Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst 96:873–875 CrossRefPubMed
Metadaten
Titel
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
verfasst von
Jean-Marc Classe
Cecile Loaec
P. Gimbergues
S. Alran
C. Tunon de Lara
P. F. Dupre
Roman Rouzier
C. Faure
N. Paillocher
M. P. Chauvet
G. Houvenaeghel
M. Gutowski
P. De Blay
J. L. Verhaeghe
E. Barranger
C. Lefebvre
C. Ngo
G. Ferron
C. Palpacuer
L. Campion
Publikationsdatum
20.10.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5004-7

Weitere Artikel der Ausgabe 2/2019

Breast Cancer Research and Treatment 2/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.